Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol (physio)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
A. Eden Evins, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01362101
First received: May 23, 2011
Last updated: July 9, 2013
Last verified: July 2013
  Purpose

This study is ancillary. Participants will be recruited as part of a separate clinical trial on effects of two intensive behavioral training programs that evaluates feasibility and efficacy of a behavioral treatment that includes mindfulness techniques (MT) in comparison to traditional behavioral therapy (CBT) for smoking cessation. The investigators propose to compare the effect of MT to that of traditional CBT on a physiological marker of stress, salivary cortisol concentration, and physiological responses to smoking cues in tobacco smokers. The investigators will use electrophysiological reactivity to smoking cues in the form of audio recordings of personalized scripts describing the scenarios associated with the strongest urges to smoke that will provide a physiological validation to a behavioral intervention. The investigators will also explore correlations between these biological markers and self report of stress, craving and negative affect to supplement self report and behavioral outcome measures with biological and physiological markers to represent improvement attributed to the intervention.


Condition Intervention Phase
Smokers
Behavioral: Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • physiologic reactivity (skin conductance, Heart rate, electromyogram, cortisol measures) to smoking cues in recently abstinent tobacco smokers [ Time Frame: It will be measured twice during the study: before treatment (baseline at week 0) and an average of 7 days after treatment (end point assessment) ] [ Designated as safety issue: No ]
    • Wk 0: development of scripts based on participant's descriptions of the most salient aspects of the smoking experience that triggers craving. Then they will undergo pre-treatment psychophysiological activation to smoking-related cues using the script driven imagery technique (smoking-related and affectively neutral scripts), in vivo cues and salivary cortisol testing.
    • Wk 4: After the last MT or CBT session, participants will undergo post-treatment psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues and salivary cortisol testing.


Secondary Outcome Measures:
  • self reported of cue-induced negative affect, craving, and stress in recently abstinent tobacco smokers [ Time Frame: It will be measured twice at the baseline assessment (before and after script driven imagery) and twice at the end point assessment (before and after script driven imagery) ] [ Designated as safety issue: No ]

Enrollment: 56
Study Start Date: July 2010
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Traditional behavioral intervention Behavioral: Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)

60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:

  • Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.
  • Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol.
Active Comparator: Mindfulness behavioral intervention Behavioral: Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)

60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:

  • Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.
  • Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Inclusion Criteria for the entire trial:

    • Women and men aged 18-65, inclusive, who are competent, wish to participate and willing to provide informed consent.
    • Self report smoking >=15 cigarettes/day.
    • Expired air CO > 9ppm at the time of enrollment.
    • Must be willing to participate in a meditation training group.
  2. Inclusion criteria for the physiological assessment:

    • Abstinent for at least 12 hrs prior to the assessment.
    • CO<15ppm
    • Have negative urine toxicology for illicit drugs or alcohol.

Exclusion Criteria:

  • DSM-IV diagnosis of dementia, neurodegenerative disease, or other organic mental disorder, lifetime history of psychotic disorder, bipolar disorder, severe PTSD, Dissociative Identity Disorder, OCD, anorexia nervosa, mental retardation, or autism.
  • History of moderate or severe major depressive episode or generalized anxiety disorder within the last 6 months.
  • Use of prescribed psychotropic medication other than SSRI/NDRI/SNRI/ buprenorphine in past 6mo, or change in such psychiatric medication dose in past six months.
  • History of active substance use disorder other than nicotine or caffeine in the last 6 months.
  • Positive urine toxicology for illicit drugs, alcohol, opiates or benzodiazepines.
  • Serious unstable medical illness including, cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease such that hospitalization for treatment of that illness is likely within the next 4 months. History of life-threatening arrhythmia, CHF, syncope, or myocardial infarction within the last year. Abnormal cardiovascular event, or uncontrolled hypertension within last 2 months.
  • History of cerebro-vascular events (i.e., stroke, TIA), multiple head injuries with neurological sequelae, a single severe head injury with lasting neurological sequelae, history of seizure disorder or current CNS tumor.
  • Use of investigational medication in the past 30 days.
  • Inability to speak, read, or understand English.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01362101

Locations
United States, Massachusetts
Center For Addiction Medicine-Massachusetts General Hospital
Boston, Massachusetts, United States, 02478
Sponsors and Collaborators
A. Eden Evins
Investigators
Principal Investigator: Gladys N Pachas, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: A. Eden Evins, Director Center for Addiction Medicine, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01362101     History of Changes
Other Study ID Numbers: 2010P-001316
Study First Received: May 23, 2011
Last Updated: July 9, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
cue reactivity
physiologic activation
craving
smoking cues
Behavioral therapy

ClinicalTrials.gov processed this record on October 19, 2014